These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23224745)

  • 1. Immunohistochemistry of cytokeratins 7, 8, 17, 18, and 19, and GLUT-1 aids differentiation of desmoplastic malignant mesothelioma from fibrous pleuritis.
    Horiuchi T; Ogata S; Tominaga S; Hiroi S; Kawahara K; Hebisawa A; Irei I; Ito I; Kameya T; Tsujimura T; Nakano T; Nakanishi K; Kawai T
    Histol Histopathol; 2013 May; 28(5):663-70. PubMed ID: 23224745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
    Husain AN; Mirza MK; Gibbs A; Hiroshima K; Chi Y; Boumendjel R; Stang N; Krausz T; Galateau-Salle F
    Lung Cancer; 2014 Mar; 83(3):324-8. PubMed ID: 24440278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma.
    Kato Y; Tsuta K; Seki K; Maeshima AM; Watanabe S; Suzuki K; Asamura H; Tsuchiya R; Matsuno Y
    Mod Pathol; 2007 Feb; 20(2):215-20. PubMed ID: 17192790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
    Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
    Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining.
    Mangano WE; Cagle PT; Churg A; Vollmer RT; Roggli VL
    Am J Clin Pathol; 1998 Aug; 110(2):191-9. PubMed ID: 9704618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
    Wu D; Hiroshima K; Matsumoto S; Nabeshima K; Yusa T; Ozaki D; Fujino M; Yamakawa H; Nakatani Y; Tada Y; Shimada H; Tagawa M
    Am J Clin Pathol; 2013 Jan; 139(1):39-46. PubMed ID: 23270897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions.
    Derakhshan F; Ionescu D; Cheung S; Churg A
    Arch Pathol Lab Med; 2020 Feb; 144(2):185-188. PubMed ID: 31484000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
    Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
    Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
    Üçer Ö; Dağli AF; Kiliçarslan A; Artaş G
    Turk Patoloji Derg; 2013; 29(2):94-100. PubMed ID: 23661345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach.
    Kuperman M; Florence RR; Pantanowitz L; Visintainer PF; Cibas ES; Otis CN
    Diagn Cytopathol; 2013 Feb; 41(2):131-40. PubMed ID: 23002041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
    Tot T
    Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
    Lagana SM; Taub RN; Borczuk AC
    Arch Pathol Lab Med; 2012 Jul; 136(7):804-9. PubMed ID: 22742553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
    Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
    J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse malignant mesothelioma.
    Oviedo SP; Cagle PT
    Arch Pathol Lab Med; 2012 Aug; 136(8):882-8. PubMed ID: 22849735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.
    Piao ZH; Zhou XC; Chen JY
    Virchows Arch; 2021 Aug; 479(2):257-263. PubMed ID: 33570661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.
    Miettinen M; Sarlomo-Rikala M
    Am J Surg Pathol; 2003 Feb; 27(2):150-8. PubMed ID: 12548160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis.
    Carella R; Deleonardi G; D'Errico A; Salerno A; Egarter-Vigl E; Seebacher C; Donazzan G; Grigioni WF
    Am J Surg Pathol; 2001 Jan; 25(1):43-50. PubMed ID: 11145250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of Site-Specific Biopsy for Diagnosis of Desmoplastic Malignant Mesothelioma.
    Sakai T; Tane K; Usui Y; Miyoshi T; Matsumoto S; Aokage K; Goto K; Suzuki M; Ishii G; Tsuboi M
    Ann Thorac Surg; 2018 Sep; 106(3):e125-e128. PubMed ID: 29601807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of GLUT-1 in distinguishing malignant mesothelioma from reactive mesothelial cells: a meta-analysis.
    Zhong SC; Ao XJ; Yu SH
    Biomarkers; 2020 Mar; 25(2):157-163. PubMed ID: 31916460
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia.
    Kushitani K; Amatya VJ; Mawas AS; Miyata Y; Okada M; Takeshima Y
    Pathobiology; 2016; 83(1):33-40. PubMed ID: 26735863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.